# A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

> **NCT01484496** · PHASE3 · COMPLETED · sponsor: **Human Genome Sciences Inc., a GSK Company** · enrollment: 839 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Belimumab 200 mg SC
- **DRUG:** Standard therapy

## Key facts

- **NCT ID:** NCT01484496
- **Lead sponsor:** Human Genome Sciences Inc., a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-16
- **Primary completion:** 2015-02-13
- **Final completion:** 2015-10-01
- **Target enrollment:** 839 (ACTUAL)
- **Last updated:** 2018-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01484496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01484496, "A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01484496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*